GeoVax Labs, Inc. — Q3 2019 Form 10-Q
Business context and period: Clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer using its MVA-VLP platform. This unaudited report covers the three and nine months ended September 30, 2019, compared with the same 2018 periods. GeoVax reported no product-sales revenue; revenue came from government grants and research collaborations.
Financial performance and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Grant and collaboration revenue | $333,209 | $349,344 | $907,382 | $663,908 |
| Research and development expense | $467,674 | $557,696 | $1,474,619 | $1,416,892 |
| General and administrative expense | $291,475 | $458,974 | $1,214,189 | $1,175,399 |
| Operating loss | $(425,940) | $(667,326) | $(1,781,426) | $(1,928,383) |
| Net loss | $(424,434) | $(666,893) | $(1,780,036) | $(1,925,749) |
| Basic and diluted loss per share | $(0.03) | $(1.99) | $(0.37) | $(6.43) |
Gross profit and operating margins are not separately reported. Revenue is recognized as grant-eligible costs are incurred or collaboration work is performed. Management cautions that interim results fluctuate and are not predictive of full-year results.
- Cash and assets: Cash was $569,359 at September 30, 2019, versus $259,701 at December 31, 2018; total assets were $816,529.
- Cash flow, nine months: Operating activities used $1,117,737 (2018: $1,041,485); investing activities used $4,272; financing activities provided $1,431,667, chiefly from preferred-stock sales. Ending cash was $569,359.
- Liquidity and debt: Working-capital deficit was $1,012,491. Total liabilities were $1,837,248, including $1,732,438 accrued expenses. Notes payable totaled $41,667, including the GRA note.
- Other obligations: Accrued management salaries and directors’ fees totaled $1,606,738 and were being deferred. Contractual obligations listed were $40,000 of remaining 2019 rent and approximately $391,000 of purchase commitments, which the company expected to be reimbursed under grants.
Material changes and capital structure
- Nine-month revenue rose to $907,382 from $663,908, mainly reflecting higher collaboration revenue and grant activity. Q3 revenue was slightly lower year over year. Nine-month net loss narrowed to $1,780,036 from $1,925,749.
- On April 30, 2019, the company effected a 1-for-500 reverse stock split. During Q3, conversion of 1,002 Series H preferred shares produced 94,687,441 common shares. Common shares outstanding were 95,627,584 at September 30; after further conversions, 426,306,328 were outstanding as of November 6.
- GeoVax raised $1.44 million in net financing proceeds from Series G and Series I preferred-stock sales during the first nine months. Convertible preferred stock has conversion-price adjustment provisions; the filing describes potential further dilution.
Outlook, risks and unusual items
- Going concern: Management said existing cash, government funding and collaboration commitments were expected to support planned operations into the first quarter of 2020. The filing states there is substantial doubt about continuing as a going concern beyond that period. Additional funding is required and may not be available on acceptable terms or at all; without it, programs and overhead may need to be reduced.
- Funding and grants: The company reported $1,835,225 in approved grant funds available for use in 2019 and 2020, of which $1,151,610 was expected to reimburse third parties. It was seeking additional grants, collaborations and equity financing.
- Programs: GeoVax described a planned HIV vaccine Phase 1 trial through HVTN, with enrollment expected in 2020 but timing uncertain, and an AGT collaboration trial expected to begin in early 2020. These are expectations, not assured milestones. The company does not provide forward cost or completion estimates for its research programs.
- Share and trading risks: Management warned that available authorized common shares might be insufficient to meet conversion and warrant obligations at prevailing trading levels, potentially resulting in investor claims or damages and constraining future equity financing. OTC Markets had notified the company of OTCQB minimum-bid noncompliance; the cure period ran to January 22, 2020, with potential removal from OTCQB if compliance was not regained.
- The office and laboratory lease expired December 31, 2019 and an extension was under negotiation. The filing reported no legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Cash runway and whether subsequent financing, grants or collaborations secured funding beyond the expected first-quarter 2020 horizon.
- Subsequent preferred-stock conversions, common shares outstanding, authorized-share capacity and the potential dilution or obligations under conversion-price adjustments and warrants.
- Progress toward OTCQB bid-price compliance and any market-status change.
- Timing and funding of the planned HIV-related clinical studies, and whether grant balances and reimbursable commitments remain available as expected.
- Status of deferred management and director compensation and renewal of the facility lease.